The research report titled “Global PD-L1 Biomarker Testing Market (2023 Edition)” provides a complete analysis of the global PD-L1 Biomarker Testing industry in terms of market segmentation by Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others), Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142), and By End Use (Research and Development, Diagnostics), by region and by country for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029. ![Global PDL-1 Biomarker Testing Market]( "Global PDL-1 Biomarker Testing Market")
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, South Korea, Australia, Japan). Additionally, the research report presents data including market size, yearly growth and potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.
The Global PD-L1 Biomarker Testing Market is expected to generate USD 27.7 Billion by the end of 2029, up from USD 1.75 Billion in 2022. During the forecast period, 2024-2029, the Global PD-L1 Biomarker Testing market is expected to grow at a CAGR of 45.80%.
PD-L1 is a variety of proteins present on the cell membranes of numerous body cells. Some tumour cells contain a high concentration of PD-L1, which enables them to evade detection and elimination by the immune system. A PD-L1 assay determines the concentration of PD-L1 in cancerous cells.
The rising prevalence of different types of cancer around the world, and especially Lung cancer has been a major driver of the market for PD-L1 biomarker testing. Furthermore, as the demand for effective cancer treatments grows, pharmaceutical companies are driven to develop novel immunotherapies and invest in companion diagnostics such as PD-L1 tests. These tests are essential components of the regulatory approval procedure for novel pharmaceuticals, hence contributing to the expansion of the market. As more individuals are diagnosed with cancer, there has been a rising demand for efficient and targeted treatments, such as immunotherapies.
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, South Korea, Australia, Japan). Additionally, the research report presents data including market size, yearly growth and potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.
The Global PD-L1 Biomarker Testing Market is expected to generate USD 27.7 Billion by the end of 2029, up from USD 1.75 Billion in 2022. During the forecast period, 2024-2029, the Global PD-L1 Biomarker Testing market is expected to grow at a CAGR of 45.80%.
PD-L1 is a variety of proteins present on the cell membranes of numerous body cells. Some tumour cells contain a high concentration of PD-L1, which enables them to evade detection and elimination by the immune system. A PD-L1 assay determines the concentration of PD-L1 in cancerous cells.
The rising prevalence of different types of cancer around the world, and especially Lung cancer has been a major driver of the market for PD-L1 biomarker testing. Furthermore, as the demand for effective cancer treatments grows, pharmaceutical companies are driven to develop novel immunotherapies and invest in companion diagnostics such as PD-L1 tests. These tests are essential components of the regulatory approval procedure for novel pharmaceuticals, hence contributing to the expansion of the market. As more individuals are diagnosed with cancer, there has been a rising demand for efficient and targeted treatments, such as immunotherapies.
Scope of the Report
- The report analyses the PD-L1 Biomarker Testing Market by Value (USD Million).
- The report presents the analysis of PD-L1 Biomarker Testing Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
- The report analyses the PD-L1 Biomarker Testing Market by Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head & neck, Bladder Cancer, Other Cancer Types).
- The report analyses the PD-L1 Biomarker Testing Market by Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 (SP263), PD-L1 (SP142)).
- The report analyses the PD-L1 Biomarker Testing Market by End Use (Research and Development, Diagnostics).
- The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by cancer type, by Assay Kits & by end uses.
- Also, the major opportunities, trends, drivers, and challenges of the industry have been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include AstraZeneca PLC, Merck Group (SigmaAldrich Co., LLC), F. Hoffmann-La Roche AG, Abcam, Agilent technologies, NeoGenomics Laboratories, Inc., ACROBiosystems, PerkinElmer Inc., Guardant Health and Quanterix.
Table of Contents
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
2.1 Advancement of PD-L1 Biomarker Testing via the Integration of Digital Pathology and Artificial Intelligence
2.2 Broad Range Biomarker Analysis Panels
2.2 Broad Range Biomarker Analysis Panels
3. Global PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
3.1 PD-L1 biomarker testing : Fact sheet
3.2 Age-standardised cancer incidence rate, 2020
3.3 Global PD-(L)1 inhibitors sales by brand
3.4 Global Prevalence of Cancer, By type
3.5 Global PD-L1 Biomarker Testing Market : Dashboard
3.6 Global PD-L1 Biomarker Testing Market: Market Value Assessment, 2019-2029 (USD Million)
3.7 Impact of COVID-19 on Global PD-L1 Biomarker Testing Market
3.8 Global PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
3.8.1 Global PD-L1 Biomarker Testing Market, By Cancer Type Overview
3.8.2 Global PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
3.8.3 Global PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
3.8.4 Global PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
3.8.5 Global PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
3.8.6 Global PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
3.8.7 Global PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
3.9 Global PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
3.9.1 Global PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
3.9.2 Global PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
3.9.3 Global PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
3.9.4 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
3.9.5 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
3.10 Global PD-L1 Biomarker Testing Market Segmentation: By End Use
3.10.1 Global PD-L1 Biomarker Testing Market, By End Use Overview
3.10.2 Global PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
3.10.3 Global PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
3.2 Age-standardised cancer incidence rate, 2020
3.3 Global PD-(L)1 inhibitors sales by brand
3.4 Global Prevalence of Cancer, By type
3.5 Global PD-L1 Biomarker Testing Market : Dashboard
3.6 Global PD-L1 Biomarker Testing Market: Market Value Assessment, 2019-2029 (USD Million)
3.7 Impact of COVID-19 on Global PD-L1 Biomarker Testing Market
3.8 Global PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
3.8.1 Global PD-L1 Biomarker Testing Market, By Cancer Type Overview
3.8.2 Global PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
3.8.3 Global PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
3.8.4 Global PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
3.8.5 Global PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
3.8.6 Global PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
3.8.7 Global PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
3.9 Global PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
3.9.1 Global PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
3.9.2 Global PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
3.9.3 Global PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
3.9.4 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
3.9.5 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
3.10 Global PD-L1 Biomarker Testing Market Segmentation: By End Use
3.10.1 Global PD-L1 Biomarker Testing Market, By End Use Overview
3.10.2 Global PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
3.10.3 Global PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
4. Global PD-L1 Biomarker Testing Market, Regional Analysis
4.1 Regional Coverage of the Study
5. Americas PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
5.1 Americas PD-L1 Biomarker Testing Market: Snapshot
5.2 Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.3 Americas PD-L1 Biomarker Testing Market: Key Factors
5.4 Americas PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
5.4.1 Americas PD-L1 Biomarker Testing Market, By Cancer Type Overview
5.4.2 Americas PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
5.4.3 Americas PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
5.4.4 Americas PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
5.4.5 Americas PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
5.4.6 Americas PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
5.4.7 Americas PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
5.5 Americas PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
5.5.1 Americas PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
5.5.2 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
5.5.3 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
5.5.4 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
5.5.5 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
5.6 Americas PD-L1 Biomarker Testing Market Segmentation: By End Use
5.6.1 Americas PD-L1 Biomarker Testing Market, By End Use Overview
5.6.2 Americas PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
5.6.3 Americas PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
5.7 Americas PD-L1 Biomarker Testing Market Segmentation : By Country
5.7.1 United States PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.1.1 United States PD-L1 Biomarker Testing Market, By Cancer Type
5.7.1.2 United States PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.1.3 United States PD-L1 Biomarker Testing Market, By End Use
5.7.2 Canada PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.2.1 Canada PD-L1 Biomarker Testing Market, By Cancer Type
5.7.2.2 Canada PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.2.3 Canada PD-L1 Biomarker Testing Market, By End Use
5.7.3 Rest of Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.3.1 Rest of Americas PD-L1 Biomarker Testing Market, By Cancer Type
5.7.3.2 Rest of Americas PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.3.3 Rest of Americas PD-L1 Biomarker Testing Market, By End Use
5.2 Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.3 Americas PD-L1 Biomarker Testing Market: Key Factors
5.4 Americas PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
5.4.1 Americas PD-L1 Biomarker Testing Market, By Cancer Type Overview
5.4.2 Americas PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
5.4.3 Americas PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
5.4.4 Americas PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
5.4.5 Americas PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
5.4.6 Americas PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
5.4.7 Americas PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
5.5 Americas PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
5.5.1 Americas PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
5.5.2 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
5.5.3 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
5.5.4 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
5.5.5 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
5.6 Americas PD-L1 Biomarker Testing Market Segmentation: By End Use
5.6.1 Americas PD-L1 Biomarker Testing Market, By End Use Overview
5.6.2 Americas PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
5.6.3 Americas PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
5.7 Americas PD-L1 Biomarker Testing Market Segmentation : By Country
5.7.1 United States PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.1.1 United States PD-L1 Biomarker Testing Market, By Cancer Type
5.7.1.2 United States PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.1.3 United States PD-L1 Biomarker Testing Market, By End Use
5.7.2 Canada PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.2.1 Canada PD-L1 Biomarker Testing Market, By Cancer Type
5.7.2.2 Canada PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.2.3 Canada PD-L1 Biomarker Testing Market, By End Use
5.7.3 Rest of Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.3.1 Rest of Americas PD-L1 Biomarker Testing Market, By Cancer Type
5.7.3.2 Rest of Americas PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.3.3 Rest of Americas PD-L1 Biomarker Testing Market, By End Use
6. Europe PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
6.1 Europe PD-L1 Biomarker Testing Market: Snapshot
6.2 Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.3 Europe PD-L1 Biomarker Testing Market: Key Factors
6.4 Europe PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
6.4.1 Europe PD-L1 Biomarker Testing Market, By Cancer Type Overview
6.4.2 Europe PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
6.4.3 Europe PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
6.4.4 Europe PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
6.4.5 Europe PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
6.4.6 Europe PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
6.4.7 Europe PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
6.5 Europe PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
6.5.1 Europe PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
6.5.2 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
6.5.5 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
6.6 Europe PD-L1 Biomarker Testing Market Segmentation: By End Use
6.6.1 Europe PD-L1 Biomarker Testing Market, By End Use Overview
6.6.2 Europe PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
6.6.3 Europe PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
6.7 Europe PD-L1 Biomarker Testing Market Segmentation : By Country
6.7.1 Germany PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.1.1 Germany PD-L1 Biomarker Testing Market, By Cancer Type
6.7.1.2 Germany PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.1.3 Germany PD-L1 Biomarker Testing Market, By End Use
6.7.2 United Kingdom PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.2.1 United Kingdom PD-L1 Biomarker Testing Market, By Cancer Type
6.7.2.2 United Kingdom PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.2.3 United Kingdom PD-L1 Biomarker Testing Market, By End Use
6.7.3 France PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.3.1 France PD-L1 Biomarker Testing Market, By Cancer Type
6.7.3.2 France PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.3.3 France PD-L1 Biomarker Testing Market, By End Use
6.7.4 Italy PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.4.1 Italy PD-L1 Biomarker Testing Market, By Cancer Type
6.7.4.2 Italy PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.4.3 Italy PD-L1 Biomarker Testing Market, By End Use
6.7.5 Spain PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.5.1 Spain PD-L1 Biomarker Testing Market, By Cancer Type
6.7.5.2 Spain PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.5.3 Spain PD-L1 Biomarker Testing Market, By End Use
6.7.6 Rest of Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.6.1 Rest of Europe PD-L1 Biomarker Testing Market, By Cancer Type
6.7.6.2 Rest of Europe PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.6.3 Rest of Europe PD-L1 Biomarker Testing Market, By End Use
6.2 Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.3 Europe PD-L1 Biomarker Testing Market: Key Factors
6.4 Europe PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
6.4.1 Europe PD-L1 Biomarker Testing Market, By Cancer Type Overview
6.4.2 Europe PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
6.4.3 Europe PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
6.4.4 Europe PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
6.4.5 Europe PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
6.4.6 Europe PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
6.4.7 Europe PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
6.5 Europe PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
6.5.1 Europe PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
6.5.2 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
6.5.5 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
6.6 Europe PD-L1 Biomarker Testing Market Segmentation: By End Use
6.6.1 Europe PD-L1 Biomarker Testing Market, By End Use Overview
6.6.2 Europe PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
6.6.3 Europe PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
6.7 Europe PD-L1 Biomarker Testing Market Segmentation : By Country
6.7.1 Germany PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.1.1 Germany PD-L1 Biomarker Testing Market, By Cancer Type
6.7.1.2 Germany PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.1.3 Germany PD-L1 Biomarker Testing Market, By End Use
6.7.2 United Kingdom PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.2.1 United Kingdom PD-L1 Biomarker Testing Market, By Cancer Type
6.7.2.2 United Kingdom PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.2.3 United Kingdom PD-L1 Biomarker Testing Market, By End Use
6.7.3 France PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.3.1 France PD-L1 Biomarker Testing Market, By Cancer Type
6.7.3.2 France PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.3.3 France PD-L1 Biomarker Testing Market, By End Use
6.7.4 Italy PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.4.1 Italy PD-L1 Biomarker Testing Market, By Cancer Type
6.7.4.2 Italy PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.4.3 Italy PD-L1 Biomarker Testing Market, By End Use
6.7.5 Spain PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.5.1 Spain PD-L1 Biomarker Testing Market, By Cancer Type
6.7.5.2 Spain PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.5.3 Spain PD-L1 Biomarker Testing Market, By End Use
6.7.6 Rest of Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.6.1 Rest of Europe PD-L1 Biomarker Testing Market, By Cancer Type
6.7.6.2 Rest of Europe PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.6.3 Rest of Europe PD-L1 Biomarker Testing Market, By End Use
7. Asia-Pacific PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
7.1 Asia-Pacific PD-L1 Biomarker Testing Market: Snapshot
7.2 Asia-Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.3 Asia-Pacific PD-L1 Biomarker Testing Market: Key Factors
7.4 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
7.4.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Cancer Type Overview
7.4.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
7.4.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
7.4.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
7.4.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
7.4.6 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
7.4.7 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
7.5 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
7.5.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
7.5.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
7.5.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
7.5.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
7.5.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
7.6 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By End Use
7.6.1 Asia-Pacific PD-L1 Biomarker Testing Market, By End Use Overview
7.6.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
7.6.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
7.7 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation : By Country
7.7.1 China PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.1.1 China PD-L1 Biomarker Testing Market, By Cancer Type
7.7.1.2 China PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.1.3 China PD-L1 Biomarker Testing Market, By End Use
7.7.2 Japan PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.2.1 Japan PD-L1 Biomarker Testing Market, By Cancer Type
7.7.2.2 Japan PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.2.3 Japan PD-L1 Biomarker Testing Market, By End Use
7.7.3 South Korea PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.3.1 South Korea PD-L1 Biomarker Testing Market, By Cancer Type
7.7.3.2 South Korea PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.3.3 South Korea PD-L1 Biomarker Testing Market, By End Use
7.7.4 Australia PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.4.1 Australia PD-L1 Biomarker Testing Market, By Cancer Type
7.7.4.2 Australia PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.4.3 Australia PD-L1 Biomarker Testing Market, By End Use
7.7.5 Rest of Asia Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Cancer Type
7.7.5.2 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.5.3 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By End Use
7.2 Asia-Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.3 Asia-Pacific PD-L1 Biomarker Testing Market: Key Factors
7.4 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
7.4.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Cancer Type Overview
7.4.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
7.4.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
7.4.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
7.4.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
7.4.6 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
7.4.7 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
7.5 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
7.5.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
7.5.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
7.5.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
7.5.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
7.5.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
7.6 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By End Use
7.6.1 Asia-Pacific PD-L1 Biomarker Testing Market, By End Use Overview
7.6.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
7.6.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
7.7 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation : By Country
7.7.1 China PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.1.1 China PD-L1 Biomarker Testing Market, By Cancer Type
7.7.1.2 China PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.1.3 China PD-L1 Biomarker Testing Market, By End Use
7.7.2 Japan PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.2.1 Japan PD-L1 Biomarker Testing Market, By Cancer Type
7.7.2.2 Japan PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.2.3 Japan PD-L1 Biomarker Testing Market, By End Use
7.7.3 South Korea PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.3.1 South Korea PD-L1 Biomarker Testing Market, By Cancer Type
7.7.3.2 South Korea PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.3.3 South Korea PD-L1 Biomarker Testing Market, By End Use
7.7.4 Australia PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.4.1 Australia PD-L1 Biomarker Testing Market, By Cancer Type
7.7.4.2 Australia PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.4.3 Australia PD-L1 Biomarker Testing Market, By End Use
7.7.5 Rest of Asia Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Cancer Type
7.7.5.2 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.5.3 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By End Use
8. Middle-East & Africa PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029 )
8.1 Middle-East & Africa PD-L1 Biomarker Testing Market: Snapshot
8.2 Middle-East & Africa PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
8.3 Middle-East & Africa PD-L1 Biomarker Testing Market: Key Factors
8.4 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
8.4.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Cancer Type Overview
8.4.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
8.4.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
8.4.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
8.4.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
8.4.6 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
8.4.7 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
8.5 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
8.5.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
8.5.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
8.5.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
8.5.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
8.5.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
8.6 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By End Use
8.6.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By End Use Overview
8.6.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
8.6.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
8.2 Middle-East & Africa PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
8.3 Middle-East & Africa PD-L1 Biomarker Testing Market: Key Factors
8.4 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
8.4.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Cancer Type Overview
8.4.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
8.4.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
8.4.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
8.4.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
8.4.6 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
8.4.7 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
8.5 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
8.5.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
8.5.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
8.5.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
8.5.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
8.5.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
8.6 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By End Use
8.6.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By End Use Overview
8.6.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
8.6.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Global PD-L1 Biomarker Testing Market
9.2 Drivers
9.3 Restraints
9.4 Trends
9.2 Drivers
9.3 Restraints
9.4 Trends
11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of PD-L1 Biomarker Testing Market
11.4 Company Profiles
11.4.1 AstraZeneca PLC
11.4.2 Merck Group (SigmaAldrich Co., LLC)
11.4.3 F. Hoffmann-La Roche AG
11.4.4 Abcam
11.4.5 Agilent technologies
11.4.6 NeoGenomics Laboratories, Inc.,
11.4.7 ACROBiosystems
11.4.8 PerkinElmer Inc.
11.4.9 Guardant Health
11.4.10 Quanterix
11.2 Market Position Matrix
11.3 Market Share Analysis of PD-L1 Biomarker Testing Market
11.4 Company Profiles
11.4.1 AstraZeneca PLC
11.4.2 Merck Group (SigmaAldrich Co., LLC)
11.4.3 F. Hoffmann-La Roche AG
11.4.4 Abcam
11.4.5 Agilent technologies
11.4.6 NeoGenomics Laboratories, Inc.,
11.4.7 ACROBiosystems
11.4.8 PerkinElmer Inc.
11.4.9 Guardant Health
11.4.10 Quanterix
List of Figures
Figure 1: Age-standardised cancer incidence rate, 2020*
Figure 2: Global PD-(L)1 sales by brand ($Bn, 2016-2021)
Figure 3: Prevalence by cancer site
Figure 4: Global PD-L1 Biomarker Testing Market Size, By Value, 2019-2022 (USD Million)
Figure 5: Global PD-L1 Biomarker Testing Market Size, By Value, 2023-2029 (USD Million)
Figure 6: Global PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 7: Global PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 8: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By NSCLC, 2019-2029 (USD Million)
Figure 9: Global PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 10: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Kidney Cancer, 2019-2029 (USD Million)
Figure 11: Global PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 12: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Melanoma, 2019-2029 (USD Million)
Figure 13: Global PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 14: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Head & neck, 2019-2029 (USD Million)
Figure 15: Global PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 16: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Bladder Cancer, 2019-2029 (USD Million)
Figure 17: Global PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 18: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Other Cancer Types, 2019-2029 (USD Million)
Figure 19: Global PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 20: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 22C3 IHC, 2019-2029 (USD Million)
Figure 21: Global PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 22: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 28-8 IHC, 2019-2029 (USD Million)
Figure 23: Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 24: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 (SP263), 2019-2029 (USD Million)
Figure 25: Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 26: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 (SP142), 2019-2029 (USD Million)
Figure 27: Global PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 28: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Research and Development, 2019-2029 (USD Million)
Figure 29: Global PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 30: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Diagnostics, 2019-2029 (USD Million)
Figure 31: Americas PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 32: Americas PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 33: Americas PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 34: Americas PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 35: Americas PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 36: Americas PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 37: Americas PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 38: Americas PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 39: Americas PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 40: Americas PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 41: Americas PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 42: Americas PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 43: Americas PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 44: Americas PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 45: United States PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 46: United States PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 47: United States PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 48: United States PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 49: United States PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 50: Canada PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 51: Canada PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 52: Canada PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 53: Canada PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 54: Canada PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 55: Rest of Americas PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 56: Rest of Americas PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 57: Rest of Americas PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 58: Rest of Americas PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 59: Rest of Americas PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 60: Europe PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 61: Europe PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 62: Europe PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 63: Europe PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 64: Europe PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 65: Europe PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 66: Europe PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 67: Europe PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 68: Europe PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 69: Europe PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 70: Europe PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 71: Europe PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 72: Europe PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 73: Europe PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 74: Germany PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 75: Germany PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 76: Germany PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 77: Germany PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 78: Germany PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 79: United Kingdom PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 80: United Kingdom PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 81: United Kingdom PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 82: United Kingdom PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 83: United Kingdom PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 84: France PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 85: France PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 86: France PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 87: France PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 88: France PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 89: Italy PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 90: Italy PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 91: Italy PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 92: Italy PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 93: Italy PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 94: Spain PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 95: Spain PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 96: Spain PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 97: Spain PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 98: Spain PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 99: Rest of Europe PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 100: Rest of Europe PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 101: Rest of Europe PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 102: Rest of Europe PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 103: Rest of Europe PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 104: Asia Pacific PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 105: Asia Pacific PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 106: Asia Pacific PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 107: Asia Pacific PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 108: Asia Pacific PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 109: Asia Pacific PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 110: Asia Pacific PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 111: Asia Pacific PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 112: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 113: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 114: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 115: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 116: Asia Pacific PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 117: Asia Pacific PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 118: China PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 119: China PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 120: China PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 121: China PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 122: China PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 123: Japan PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 124: Japan PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 125: Japan PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 126: Japan PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 127: Japan PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 128: South Korea PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 129: South Korea PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 130: South Korea PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 131: South Korea PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 132: South Korea PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 133: Australia PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 134: Australia PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 135: Australia PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 136: Australia PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 137: Australia PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 138: Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 139: Rest of Asia Pacific PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 140: Rest of Asia Pacific PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 141: Rest of Asia Pacific PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 142: Rest of Asia Pacific PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 143: Middle East and Africa PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 144: Middle East and Africa PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 145: Middle East and Africa PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 146: Middle East and Africa PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 147: Middle East and Africa PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 148: Middle East and Africa PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 149: Middle East and Africa PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 150: Middle East and Africa PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 151: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 152: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 153: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 154: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 155: Middle East and Africa PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 156: Middle East and Africa PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 157: Global Impact of Drivers and Restraints
Figure 158: Market Share of Prominent Companies of PD-L1 Biomarker Testing Market, 2022 (%)
Figure :159 AstraZeneca PLC Revenues, 2020-2022 (USD Million)
Figure 160: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
Figure 161: AstraZeneca PLC Revenue, By Business Segments, 2022 (%)
Figure 162: Merck Group Revenues, 2020-2022 (USD Million)
Figure 2: Global PD-(L)1 sales by brand ($Bn, 2016-2021)
Figure 3: Prevalence by cancer site
Figure 4: Global PD-L1 Biomarker Testing Market Size, By Value, 2019-2022 (USD Million)
Figure 5: Global PD-L1 Biomarker Testing Market Size, By Value, 2023-2029 (USD Million)
Figure 6: Global PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 7: Global PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 8: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By NSCLC, 2019-2029 (USD Million)
Figure 9: Global PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 10: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Kidney Cancer, 2019-2029 (USD Million)
Figure 11: Global PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 12: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Melanoma, 2019-2029 (USD Million)
Figure 13: Global PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 14: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Head & neck, 2019-2029 (USD Million)
Figure 15: Global PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 16: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Bladder Cancer, 2019-2029 (USD Million)
Figure 17: Global PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 18: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Other Cancer Types, 2019-2029 (USD Million)
Figure 19: Global PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 20: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 22C3 IHC, 2019-2029 (USD Million)
Figure 21: Global PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 22: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 28-8 IHC, 2019-2029 (USD Million)
Figure 23: Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 24: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 (SP263), 2019-2029 (USD Million)
Figure 25: Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 26: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By PD-L1 (SP142), 2019-2029 (USD Million)
Figure 27: Global PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 28: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Research and Development, 2019-2029 (USD Million)
Figure 29: Global PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 30: Global PD-L1 Biomarker Testing Market Absolute Opportunity, By Diagnostics, 2019-2029 (USD Million)
Figure 31: Americas PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 32: Americas PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 33: Americas PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 34: Americas PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 35: Americas PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 36: Americas PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 37: Americas PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 38: Americas PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 39: Americas PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 40: Americas PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 41: Americas PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 42: Americas PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 43: Americas PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 44: Americas PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 45: United States PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 46: United States PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 47: United States PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 48: United States PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 49: United States PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 50: Canada PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 51: Canada PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 52: Canada PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 53: Canada PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 54: Canada PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 55: Rest of Americas PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 56: Rest of Americas PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 57: Rest of Americas PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 58: Rest of Americas PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 59: Rest of Americas PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 60: Europe PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 61: Europe PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 62: Europe PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 63: Europe PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 64: Europe PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 65: Europe PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 66: Europe PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 67: Europe PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 68: Europe PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 69: Europe PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 70: Europe PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 71: Europe PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 72: Europe PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 73: Europe PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 74: Germany PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 75: Germany PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 76: Germany PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 77: Germany PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 78: Germany PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 79: United Kingdom PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 80: United Kingdom PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 81: United Kingdom PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 82: United Kingdom PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 83: United Kingdom PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 84: France PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 85: France PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 86: France PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 87: France PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 88: France PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 89: Italy PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 90: Italy PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 91: Italy PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 92: Italy PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 93: Italy PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 94: Spain PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 95: Spain PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 96: Spain PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 97: Spain PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 98: Spain PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 99: Rest of Europe PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 100: Rest of Europe PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 101: Rest of Europe PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 102: Rest of Europe PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 103: Rest of Europe PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 104: Asia Pacific PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 105: Asia Pacific PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 106: Asia Pacific PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 107: Asia Pacific PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 108: Asia Pacific PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 109: Asia Pacific PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 110: Asia Pacific PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 111: Asia Pacific PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 112: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 113: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 114: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 115: Asia Pacific PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 116: Asia Pacific PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 117: Asia Pacific PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 118: China PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 119: China PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 120: China PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 121: China PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 122: China PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 123: Japan PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 124: Japan PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 125: Japan PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 126: Japan PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 127: Japan PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 128: South Korea PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 129: South Korea PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 130: South Korea PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 131: South Korea PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 132: South Korea PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 133: Australia PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 134: Australia PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 135: Australia PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 136: Australia PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 137: Australia PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 138: Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 139: Rest of Asia Pacific PD-L1 Biomarker Testing Market Value, By Assay Kit Type, 2022 (USD Million)
Figure 140: Rest of Asia Pacific PD-L1 Biomarker Testing Market Share, By Cancer Type, By Value, 2022 (%)
Figure 141: Rest of Asia Pacific PD-L1 Biomarker Testing Market Share, By Assay Kit Type, 2022 (%)
Figure 142: Rest of Asia Pacific PD-L1 Biomarker Testing Market Share, By End Use, 2022 (%)
Figure 143: Middle East and Africa PD-L1 Biomarker Testing Market Size, By Value, 2019H-2029F (USD Million)
Figure 144: Middle East and Africa PD-L1 Biomarker Testing Market Share, By Cancer Type, 2022 (%)
Figure 145: Middle East and Africa PD-L1 Biomarker Testing Market, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 146: Middle East and Africa PD-L1 Biomarker Testing Market, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
Figure 147: Middle East and Africa PD-L1 Biomarker Testing Market, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
Figure 148: Middle East and Africa PD-L1 Biomarker Testing Market, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
Figure 149: Middle East and Africa PD-L1 Biomarker Testing Market, By Bladder, By Value, 2019H-2029F (USD Million & CAGR)
Figure 150: Middle East and Africa PD-L1 Biomarker Testing Market, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
Figure 151: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 152: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
Figure 153: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 (SP263), By Value, 2019H-2029F (USD Million & CAGR)
Figure 154: Middle East and Africa PD-L1 Biomarker Testing Market, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
Figure 155: Middle East and Africa PD-L1 Biomarker Testing Market, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
Figure 156: Middle East and Africa PD-L1 Biomarker Testing Market, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 157: Global Impact of Drivers and Restraints
Figure 158: Market Share of Prominent Companies of PD-L1 Biomarker Testing Market, 2022 (%)
Figure :159 AstraZeneca PLC Revenues, 2020-2022 (USD Million)
Figure 160: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
Figure 161: AstraZeneca PLC Revenue, By Business Segments, 2022 (%)
Figure 162: Merck Group Revenues, 2020-2022 (USD Million)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 270 |
| Published | September 2023 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 4.2 Billion |
| Forecasted Market Value ( USD | $ 27.71 Billion |
| Compound Annual Growth Rate | 45.8% |
| Regions Covered | Global |
